| abstract |
Disclosed are compositions of recombinant human lysosomal lipase (rhLAL), truncated recombinant human LAL (TLAL), an isolated mixture comprising TLAL, and at least one other form of rhLAL comprising an N-terminal truncate. A method for purifying TLAL from a mixture of LAL proteins, a pharmaceutical composition comprising TLAL and a method for producing TLAL are further disclosed. |